- Home
- Publications
- Publication Search
- Publication Details
Title
Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
Authors
Keywords
-
Journal
DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-24
DOI
10.1007/s40265-020-01437-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blood neurofilament light levels segregate treatment effects in multiple sclerosis
- (2020) Bénédicte Delcoigne et al. NEUROLOGY
- Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data
- (2020) Christoph Ohlmeier et al. PLoS One
- Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
- (2020) Tjalf Ziemssen et al. CNS DRUGS
- Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223
- (2020) Brian Steingo et al. JOURNAL OF NEUROLOGY
- Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe
- (2019) Carmen Alcalá et al. JOURNAL OF NEUROLOGY
- Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
- (2019) Adam Cuker et al. Multiple Sclerosis Journal
- Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis
- (2019) Jessica Frau et al. JOURNAL OF NEUROLOGY
- Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
- (2019) Richard Phelps et al. Multiple Sclerosis Journal
- Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)
- (2019) Sandra Vukusic et al. Multiple Sclerosis and Related Disorders
- Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study
- (2019) Jessica Frau et al. JOURNAL OF NEUROLOGY
- Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
- (2019) Tobias Ruck et al. EBioMedicine
- Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis
- (2019) L. Scappaticcio et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies
- (2019) Giancarlo Comi et al. Multiple Sclerosis Journal
- Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
- (2019) Bart Van Wijmeersch et al. Multiple Sclerosis Journal
- Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
- (2019) Heinz Wiendl et al. Neurology-Neuroimmunology & Neuroinflammation
- Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis
- (2019) E Signoriello et al. Multiple Sclerosis and Related Disorders
- Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
- (2019) Nora Möhn et al. Neurology-Neuroimmunology & Neuroinflammation
- Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus
- (2018) Catherine Lambert et al. ACTA NEUROLOGICA BELGICA
- Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management
- (2018) Brigitte Decallonne et al. ACTA NEUROLOGICA BELGICA
- Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010
- (2018) Simon Faissner et al. CNS DRUGS
- Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features
- (2018) Nadia Pariani et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations
- (2018) Virginia Devonshire et al. JOURNAL OF NEUROLOGY
- Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study
- (2018) Konstantin Huhn et al. JOURNAL OF NEUROLOGY
- Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients
- (2018) Li Wang et al. MEDICINE
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England
- (2018) Robert Hettle et al. JOURNAL OF MEDICAL ECONOMICS
- Clinical Pharmacology of Alemtuzumab, an Anti-CD52 Immunomodulator, in Multiple Sclerosis
- (2018) Zhaoyang Li et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System
- (2018) Ippazio Cosimo Antonazzo et al. Multiple Sclerosis Journal
- Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study
- (2018) Sibyl Wray et al. Multiple Sclerosis Journal
- Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria
- (2018) Evelyn Walter et al. JOURNAL OF MEDICAL ECONOMICS
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
- (2017) Tomas Kalincik et al. LANCET NEUROLOGY
- Alemtuzumab CARE-MS I 5-year follow-up
- (2017) Eva Havrdova et al. NEUROLOGY
- Alemtuzumab CARE-MS II 5-year follow-up
- (2017) Alasdair J. Coles et al. NEUROLOGY
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
- (2017) David Baker et al. JAMA Neurology
- Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility
- (2017) Stephen M. Montgomery et al. JOURNAL OF MEDICAL ECONOMICS
- Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
- (2017) Óscar Fernández Multiple Sclerosis and Related Disorders
- Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
- (2017) Eva Havrdova et al. Therapeutics and Clinical Risk Management
- Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
- (2016) Thomas Berger et al. CNS DRUGS
- Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
- (2016) Rafael Arroyo González et al. Multiple Sclerosis Journal
- Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort
- (2016) MD Willis et al. Multiple Sclerosis Journal
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
- (2016) Douglas L. Arnold et al. NEUROLOGY
- Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
- (2016) Rafael Arroyo González et al. Multiple Sclerosis Journal
- Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort
- (2016) MD Willis et al. Multiple Sclerosis Journal
- Alemtuzumab: A Review of Its Use in Patients with Relapsing Multiple Sclerosis
- (2014) Karly P. Garnock-Jones DRUGS
- Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
- (2014) O. Tuohy et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis
- (2013) Gilbert H. Daniels et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis
- (2013) X. Zhang et al. JOURNAL OF IMMUNOLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab
- (2012) T. Button et al. Multiple Sclerosis Journal
- Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis
- (2012) M. D. Cossburn et al. NEUROLOGY
- Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial
- (2012) A. J. Coles et al. NEUROLOGY
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started